Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies

NCT02649673 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT02649673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02649673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 1
Overall status
Terminated
Start date
March 23, 2016
Completion date
July 30, 2021
Enrollment
34 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, small cell lung cancer